UB Paderborn / Katalog / Suche / in CDI

The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review

Expert review of clinical immunology, 2020-03, Vol.16 (3), p.239-252

2020

Link zum Volltext

Verfügbarkeit prüfen

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists

Dermatology and therapy, 2021-04, Vol.11 (2), p.529-541

2021

Link zum Volltext

Verfügbarkeit prüfen

The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review

Expert review of clinical immunology, 2020-03, Vol.16 (3), p.253-266

2020

Link zum Volltext

Verfügbarkeit prüfen

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS

Frontiers in pharmacology, 2023-08, Vol.14, p.1241524-1241524

2023

Link zum Volltext

Verfügbarkeit prüfen

A systematic review and meta-analysis of misuse of antibiotic therapies in the community

International journal of antimicrobial agents, 2005-08, Vol.26 (2), p.106-113

2005

Link zum Volltext

Verfügbarkeit prüfen

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Gynecologic oncology reports, 2024-02, Vol.51, p.101332-101332, Article 101332

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance

Oncology and therapy, 2023-06, Vol.11 (2), p.245-261

2023

Link zum Volltext

Verfügbarkeit prüfen

Levetiracetam Pregnancy Registry: Final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations

Birth defects research, 2019-08, Vol.111 (13), p.872-887

2019

Link zum Volltext

Verfügbarkeit prüfen

Integration of a Teratologist's clinical review of birth defects reported through pharmacovigilance

Reproductive toxicology (Elmsford, N.Y.), 2016-09, Vol.64, p.38-38

2016

Link zum Volltext

Verfügbarkeit prüfen

Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5592-5592

2023

Link zum Volltext

Verfügbarkeit prüfen

Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study

Carcinogenesis (New York), 2008-10, Vol.29 (10), p.1944-1949

2008

Link zum Volltext

Verfügbarkeit prüfen

196 Has the introduction of poly(ADP-Ribose) polymerase inhibitors changed the advanced ovarian cancer treatment pathway? A bird’s-eye view of the English advanced ovarian cancer treatment landscape

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A300-A301

2024

Link zum Volltext

Verfügbarkeit prüfen

VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: A lens into the financial and quality of life (QoL) impact of disease burden and ethnic disparities reported directly by the patient

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.274-274

2022

Link zum Volltext

Verfügbarkeit prüfen

168 Identifying concepts to design a discrete choice experiment to understand patient and caregiver preferences for combination therapy in ovarian cancer

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A253-A253

2023

Link zum Volltext

Verfügbarkeit prüfen

Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200)

Gynecologic oncology, 2023-09, Vol.176, p.S257-S257

2023

Link zum Volltext

Verfügbarkeit prüfen

2022-RA-949-ESGO VOCAL (views of ovarian cancer patients-how maintenance therapy affects their lives) study: patient preference for treatment formulation and administration

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A283-A284

2022

Link zum Volltext

Verfügbarkeit prüfen

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

Future oncology (London, England), 2018-11, Vol.14 (27), p.2861-2874

2018

Link zum Volltext

Verfügbarkeit prüfen

S0849 Characteristics of Patients With Crohn’s Disease by History of Perianal Fistula Who Enrolled in the Corrona® Inflammatory Bowel Disease Registry

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S438-S439

2020

Link zum Volltext

Verfügbarkeit prüfen

26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB108-AB108

2021

Link zum Volltext

Verfügbarkeit prüfen

25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB4-AB4

2021

Link zum Volltext

Verfügbarkeit prüfen

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol

Journal of rheumatology, 2015-12, Vol.42 (12), p.2270

2015

Link zum Volltext

Verfügbarkeit prüfen

2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A258-A259

2022

Link zum Volltext

Verfügbarkeit prüfen

197 What is the real-world risk of MDS/AML and other secondary primary malignancies in patients with epithelial ovarian cancer treated with niraparib maintenance treatment? Interim results from a regulatory safety study

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A301-A302

2024

Link zum Volltext

Verfügbarkeit prüfen

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

Future oncology (London, England), 2019-05, Vol.15 (13), p.1493-1504

2019

Link zum Volltext

Verfügbarkeit prüfen

The power of hope: Views of Ovarian Cancer patients on how maintenance therapy Affects their Lives (VOCAL)

Future oncology (London, England), 2024-01, Vol.20 (2), p.83-94

2024

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists

The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS

A systematic review and meta-analysis of misuse of antibiotic therapies in the community

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance

Levetiracetam Pregnancy Registry: Final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations

Integration of a Teratologist's clinical review of birth defects reported through pharmacovigilance

Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer

Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study

196 Has the introduction of poly(ADP-Ribose) polymerase inhibitors changed the advanced ovarian cancer treatment pathway? A bird’s-eye view of the English advanced ovarian cancer treatment landscape

VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: A lens into the financial and quality of life (QoL) impact of disease burden and ethnic disparities reported directly by the patient

168 Identifying concepts to design a discrete choice experiment to understand patient and caregiver preferences for combination therapy in ovarian cancer

Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200)

2022-RA-949-ESGO VOCAL (views of ovarian cancer patients-how maintenance therapy affects their lives) study: patient preference for treatment formulation and administration

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

S0849 Characteristics of Patients With Crohn’s Disease by History of Perianal Fistula Who Enrolled in the Corrona® Inflammatory Bowel Disease Registry

26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry

25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol

2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?

197 What is the real-world risk of MDS/AML and other secondary primary malignancies in patients with epithelial ovarian cancer treated with niraparib maintenance treatment? Interim results from a regulatory safety study

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

The power of hope: Views of Ovarian Cancer patients on how maintenance therapy Affects their Lives (VOCAL)

Suchergebnisse filtern